Russian Journal of BiotherapyRussian Journal of BiotherapyРоссийский биотерапевтический журнал1726-97841726-9792Publishing House ABV Press87210.17650/1726-9784-2017-16-2-97-102ORIGINAL REPORTSОРИГИНАЛЬНЫЕ СТАТЬИThe effectiveness of combined therapy of dyslipidemia by atorvastatin and biologycally active substances from marine hydrobiontsЭффективность комбинированной терапии дислипидемии аторвастатином и биологически активными веществами из морских гидробионтовKrizshanovskyS. P.КрыжановскийС. П.
Russian Federation
GeltserB. I.ГельцерБ. И.
Russian Federation
KuznetsovaT. A.КузнецоваТ. А.
Russian Federation
PersiyanovaE. V.ПерсияноваЕ. В.
Russian Federation
helen-pers@yandex.ruZaporozhetsT. S.ЗапорожецТ. С.
Russian Federation
Medical Association of Far East Branch of Russian Academy of ScienceФГБУЗ «Медицинское объединение Дальневосточного отделения РАН»Far Eastern Federal University, School of biomedicineФГАОУ ВО «Дальневосточный федеральный университет», Школа биомедициныG.P. Somov Research Institute of Epidemiology and MicrobiologyФГБНУ«Научно-исследовательский институт эпидемиологии и микробиологии им. Г.П. Сомова»300620171629710210042018https://bioterapevt.abvpress.ru/jour/article/view/872

Introduction. The perspective direction in therapy of dyslipidemia (DLP) is a complex application of biologycally active substances from marine hydrobionts. Objective. The purpose of research - to compare the lipidcorrective action of preparates based on biologically active substances from marine hydrobionts - fukolam and maristim - individually and in combination with atorvastatin in patients with DLP. Materials and methods. 250patients with DLP and 40 healthy donors were included in research. As medicines atorvastatin, fukolam, maristim were used. In the blood serum the levels of lipid spectrum were determined. Results. Hypolipidemic action of fukolam in complex of basic therapy of patients with DLP was implemented by gradually reducing the total cholesterol, cholesterol of low-density lipoproteins, triglycerides levels to control values. The efficacy of fukolam was comparable with that of atorvastatin in a daily dose of 10 mg. Complex of «fukolam-maristim» showed hypolipidemic effect in severe hyperlipidemia. Conclusions. Combined therapy with use of bioactive substances of natural origin may be one of the way to improve the efficiency of hypolipidemic therapy. We have developed the algorithm of differential correction of DLP by inclusion the fukolam and maristim in complex therapy.

дислипидемиялипиды кровистатиныфукоиданыбиологически активные комплексы из икры морских ежейdyslipidemiablood lipidsstatinsfucoidanbiologically active complexes from sea urchin eggsChatzizisis Y.S., Koskinas K.C., Misirli G. et al. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 2010;33(3):171-87. DOI: 10.2165/11319380-000000000-00000. PMID: 20158283.Maldonado R.J.M., Lumbreras B., Jimenes M.H. et al. A pilot study in a community pharmacy to determine the efficiency and the effectiveness of statin prescriptions. Aten Primaria 2015;47(5):294-300. DOI: 10.1016/j.aprim.2014.05.016. PMID: 25262591.Kim M.J., Jeon J., Lee J.S. Fucoidan prevents high-fat diet-induced obesity in animals by suppression of fat accumulation. Phytother Res 2014;28(1):137-43. DOI: 10.1002/ptr.4965. PMID: 23580241.Huang L., Wen K., Gao X., Liu Y. Hypolipidemic effect of fucoidan from Laminaria japonica in hyperlipidemic rats. Pharm Biol 2010;48(4):422-6. DOI: 10.3109/13880200903150435. PMID: 20645721.Matloub A.A., El-Sherbini M., Borai I.H. et al. Assessment of anti-hyperlipidemic effect and physco-chemical characterization of water soluble polysaccharides from Ulva Fasciata Delile. J Appl Sci Res 2013;9(4):2983-93.Майстровский К.В., Раповка В.Г., Запорожец Т.С. Применение полисахаридов бурых водорослей в комплексном лечении облитерирующего атеросклероза сосудов нижних конечностей. Владивосток: Дальнаука, 2014. 123 с.Крыжановский С.П., Гельцер Б.И., Запорожец Т.С. и др. Бурые водоросли Тихого океана в лечении и профилактике атеросклероза. Владивосток: Дальнаука, 2016. 152 с.Fitton J.H., Stringer D.N., Karpiniec S.S. Therapies from fucoidan. Mar Drugs 2015;13(9):5920-46. DOI: 10.3390/md13095920. PMID: 26389927.Zaporozhets T., Besednova N. Prospects for the therapeutic application of sulfated polysaccharides of brown algae in diseases of the cardiovascular system: review. Pharm Biol 2016; 54(12):3126-35. DOI: 10.1080/13880209.2016.1185444. PMID: 27252012.Ковалев Н.Н., Крыжановский С.П., Кузнецова Т.А. и др. Морские ежи: биомедицинские аспекты практического применения. Владивосток: Даль-наука, 2016. 126 с.Крыжановский С.П., Кузнецова Т.А., Запорожец Т.С., Макаренкова И.Д. Влияние биологически активной добавки к пище из икры морских ежей на биохимические показатели крови мышей при алиментарной гиперхолестеринемии. Тихоокеанский медицинский журнал 2011;1:62-4.Фукоиданы - сульфатированные полисахариды бурых водорослей. Структура, ферментативная трансформация и биологические свойства. Под ред. Н.Н. Беседновой, Т.Н. Звягинцевой. Владивосток: Дальнаука, 2014. 380 с.Panlasigui L.N., Baello O.Q., Dimantangal I.M., Dumelod B.D. Blood cholesterol and lipid-lowering effects of carrageenan on human volunteers. Asia Pac J Clin Nutr 2003;12(2):209-14. PMID: 12810413.Kim Z., Lhkineev F., Khusnullina E., Gaifullina R. The use of histochrome in the complex treatment of the patients with acute coronary syndrome with ST segment depression diagnosed on ECG. Modern Appl Sci 2015;9(1): 161-9. DOI:10.5539/mas.v9n1p161.